Maria C. Smith, Ph.D.

CYLTEZO® To Launch On July 1 As The First Interchangeable HUMIRA® Biosimilar

Proposed USPTO Fee Changes Could Impact PGR And IPR Filing Strategies Used By Biosimilars

Proposed USPTO Fee Changes Will Make It Much More Expensive To Patent And To Challenge Patents On Therapeutics. You Have An Opportunity To Comment...

Celltrion Launches VEGZELMA In The United States

Coherus Biosciences Announces Approval Of A Pegfilgrastim Autoinjector

Sandoz Denosumab BLA Accepted By FDA

USPTO Launches The Cancer Moonshot Expedited Examination Pilot Program

Decision Time: The Unified Patent Court Begins In 2023

Biocon Biologics Confirms Completion Of Multi-Billion Dollar Acquisition Of Viatris' Global Biosimilars Business

China Approves World's First Denosumab Biosimilar